🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

New study - what happens to physician turnover after PE *exits* (we know more leave after PE purchase but exit hasn’t been studied).

Join us!

Congratulations to ASHEcon 2025 Diversity Scholar Winner Lady Ikeya! We are grateful to Arnold Ventures and @CompassLexecon for generously sponsoring these scholarships. Join us in Nashville for the #ASHEcon2025 Annual Conference. Learn more: ashecon.org/2025-nashville/

Check out my new paper in the May 2025 issue of Health Affairs published ahead-of-print. Thank you to my incredible co-authors and NIHCM for funding support!

Congratulations!

So excited our paper on the US generic drug market is out Thank you Heidi L. Williams & Timothy Taylor Marta Wosinska

My colleagues Helen Levy and Tom Buchmueller have an excellent piece for The Brookings Institution working through the studies -- most of them relatively new -- on how much Medicaid improves health. (link below)

New AAP Journals: using national data, we show that the Adderall shortage caused some children using this drug to switch to other stimulants. Other children stopped using stimulants altogether, especially Medicaid patients. U-M IHPI CHEAR Rena Conti publications.aap.org/pediatrics/art…

Congratulations!

This piece is very ill informed, as it ignores 1. There is legislation introduced/pending that could support capping rx pricing & 2. Medicare is already negotiating drug prices for selected drugs which MFN could build upon. The BMJ 😮‍💨

I am so honored to join this fantastic conference. We are going to learn so much from each other! And there is Irish whiskey :) Join us! Questrom School of Business, Boston University Susan Fournier

And will likely deter entry from firms that do not meet these criteria, leading to higher prices. No wonder brand firms like this: faster route to profit, higher profits over time and less competition. Sigh

New article in the Economic History Review -- public health reforms targeted at certain prevalent diseases in post-Risorgimento Italy had particularly strong effect in low-human capital areas of the country (i.e., in the South).

Yes & there is a deterrence effect, increasing prices, not great for patients or payers.

No, its a hot mess, which will likely reduce consumer choice, competition and raise prices, a very half baked policy

Congrats to Yulya Truskinovsky yulya truskinovsky of Maxwell School for her AJHE award at ASHEcon! #ASHEcon2025

Guido 👏👏👏👏👏Thank you

New pub JAMA Health Forum: we estimated the association between cost-sharing and buprenorphine dispensing by exploiting the abrupt increase in cost-sharing at the beginning of the calendar year, when deductibles reset in private and Medicare plans Kao-Ping Chua Rena Conti

A $10 increase in buprenorphine cost-sharing was estimated to have no effect on prescription abandonment for commercially insured patients and a slight increase for #Medicare-insured patients. ja.ma/3ItG4Es Rena Conti @poojalagisetty Kao-Ping Chua

The U.S. has reached its highest annual measles case tally in 33 years, and the virus - once largely extinguished - may again become endemic in the U.S. as vaccination rates fall, with continued clusters and outbreaks. via LenaSun The Washington Post washingtonpost.com/health/2025/07…